| 000 | 02033cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030912.0 | ||
| 008 | 131209s2013 ua h f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.28.Ph.D.2013.Mo.C | ||
| 100 | 0 | _aMohamed Salah Ali Mohamed Ghonaim | |
| 245 | 1 | 0 |
_aCalcimimetic (Cinacalcet) versus conventional treatment of secondary hyperparathyroidism in children with end-stage renal disease on regular hemodialysis / _cMohamed Salah Ali Mohamed Ghonaim ; Supervised Fatina Ibrahim Fadel , Samar M. Sabry Ahmed , Mohamed Farouk Mohamed |
| 246 | 1 | 5 | _aمقارنة محفزات الكالسيوم (سناكالسيت) بالعلاج التقليدى لإرتفاع هرمون الغده الجار درقيه الثانوى فى أطفال الفشل الكلوى النهائى على الاستصفاء الدموى الدورى |
| 260 |
_aCairo : _bMohamed Salah Ali Mohamed Ghonaim , _c2013 |
||
| 300 |
_a129 P. : _bfacsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pediatrics | ||
| 520 | _aKidney plays an important role in regulation of bone and mineral homeostasis, patients with chronic kidney disease (CKD) almost always have mineral and bone disorder "CKD-MDD". As CKD progresses, PTH level increases due to altered 1,25-dihydroxy vitamin D (calcitriol) metabolism, hypocalcemia and hyperphosphatemia. Control of metabolic derangements related to bone disease is one of the important goals in management of patients with CKD | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCinacalcet | |
| 653 | 4 | _aHemodiafiltration | |
| 653 | 4 | _aHemodialysis | |
| 700 | 0 |
_aFatina Ibrahim Fadel , _eSupervisor |
|
| 700 | 0 |
_aMohamed Farouk Mohamed , _eSupervisor |
|
| 700 | 0 |
_aSamar Mohamed Sabry Ahmed , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c44362 _d44362 |
||